FDA panel supports cardiovascular indication for Novo’s diabetes drug Victoza

20th June 2017 Uncategorised 0

Following a daylong meeting on Tuesday, an FDA expert panel voted to recommend a label update for Novo’s blockbuster diabetes drug Victoza stating the med can lower cardiovascular risks for high risk type 2 diabetes patients.

More: FDA panel supports cardiovascular indication for Novo’s diabetes drug Victoza
Source: fierce